X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DR. REDDYS LAB - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DR. REDDYS LAB FRESENIUS KABI ONCO./
DR. REDDYS LAB
 
P/E (TTM) x 22.1 30.5 72.5% View Chart
P/BV x 3.1 3.0 104.1% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 FRESENIUS KABI ONCO.   DR. REDDYS LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DR. REDDYS LAB
Mar-17
FRESENIUS KABI ONCO./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1763,397 5.2%   
Low Rs792,560 3.1%   
Sales per share (Unadj.) Rs37.7856.5 4.4%  
Earnings per share (Unadj.) Rs5.178.0 6.5%  
Cash flow per share (Unadj.) Rs6.7139.9 4.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs42.5739.8 5.8%  
Shares outstanding (eoy) m158.23165.74 95.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.43.5 97.1%   
Avg P/E ratio x25.038.2 65.4%  
P/CF ratio (eoy) x18.921.3 88.9%  
Price / Book Value ratio x3.04.0 74.3%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m20,135493,632 4.1%   
No. of employees `0001.222.7 5.1%   
Total wages/salary Rs m70331,068 2.3%   
Avg. sales/employee Rs Th5,176.26,259.0 82.7%   
Avg. wages/employee Rs Th610.41,369.8 44.6%   
Avg. net profit/employee Rs Th699.6569.7 122.8%   
INCOME DATA
Net Sales Rs m5,963141,961 4.2%  
Other income Rs m181,715 1.0%   
Total revenues Rs m5,981143,676 4.2%   
Gross profit Rs m1,43024,722 5.8%  
Depreciation Rs m25810,266 2.5%   
Interest Rs m-26634 -4.1%   
Profit before tax Rs m1,21615,537 7.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,965 11.5%   
Profit after tax Rs m80612,921 6.2%  
Gross profit margin %24.017.4 137.7%  
Effective tax rate %28.119.1 147.4%   
Net profit margin %13.59.1 148.5%  
BALANCE SHEET DATA
Current assets Rs m5,10296,837 5.3%   
Current liabilities Rs m2,38584,199 2.8%   
Net working cap to sales %45.68.9 511.7%  
Current ratio x2.11.2 186.0%  
Inventory Days Days15073 204.5%  
Debtors Days Days11398 116.0%  
Net fixed assets Rs m5,148102,552 5.0%   
Share capital Rs m158829 19.1%   
"Free" reserves Rs m6,556121,792 5.4%   
Net worth Rs m6,732122,621 5.5%   
Long term debt Rs m9525,449 17.5%   
Total assets Rs m10,388218,165 4.8%  
Interest coverage x-45.825.5 -179.5%   
Debt to equity ratio x0.10 318.3%  
Sales to assets ratio x0.60.7 88.2%   
Return on assets %7.56.2 120.8%  
Return on equity %12.010.5 113.6%  
Return on capital %14.612.9 113.2%  
Exports to sales %74.554.6 136.4%   
Imports to sales %24.89.4 265.0%   
Exports (fob) Rs m4,44177,520 5.7%   
Imports (cif) Rs m1,47713,274 11.1%   
Fx inflow Rs m5,29881,670 6.5%   
Fx outflow Rs m1,77226,355 6.7%   
Net fx Rs m3,52555,315 6.4%   
CASH FLOW
From Operations Rs m1,27421,444 5.9%  
From Investments Rs m-1,204-18,404 6.5%  
From Financial Activity Rs m-196-3,692 5.3%  
Net Cashflow Rs m-126-1,144 11.0%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 9.6 35.3 27.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   42,599 75,885 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - DIVIS LABORATORIES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS